Find and Pitch Jounalists, Get Your Story Covered

Tags: Paris breath bacterial endocarditis trauma nursing

	Profile	Recent Articles on Subject
1	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma - 16 days ago Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation - 17 days ago Mezigdomide Combinations Show Promise in Multiple Myeloma - 18 days ago Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 6 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - about 1 year ago Why Some Myeloma Patients Refuse Stem Cell Transplant - about 1 year ago Emerging Biomarkers of Multiple Sclerosis in Blood and CSF - about 1 year ago
2	Amir Ali, PharmD, BCOP Pharmacy Times Clinical Hem/Onc Pharmacist. USC Assistant Professor. Founder of OncologySolutionsRx. Los Angeles, CA Healthcareoncologypharmacyeducation	Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies - 19 days ago Final Thoughts - about 2 months ago Personalizing Treatments and Patient Education - 2 months ago Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7 - 3 months ago Real-World Considerations for New Therapies - 3 months ago Impact of Transplant Eligibility on Treatment Selection - 3 months ago
3	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More - about 1 month ago
4	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Daratumumab Demonstrates Significant Benefit in High-Risk Smoldering Myeloma: Results from the Phase 3 AQUILA Study - about 1 month ago Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma - 3 months ago Relapsed/Refractory Multiple Myeloma Treatment Advances With Three BiTE Therapy Options - 9 months ago AI Model Can Differentiate Prefibrotic Primary Myelofibrosis From Essential Thrombocythemia With High Accuracy - about 1 year ago
5	Ryan Haumschild, PharmD, MS, MBA Pharmacy Times Director of Pharmacy. Editorial Board member. Atlanta, Georgia pharmacyhealthcareeditorial workadvisory	Operationalizing Bispecific Therapy and the Impact of CAR-T Advancements on Sequencing - about 2 months ago
6	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Arcellx to present positive data on multiple myeloma treatments - 2 months ago
7	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit - 2 months ago
8	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma - 3 months ago All-Oral Therapy Promising in Higher-Risk MDS, CMML - 11 months ago
9	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Luspatercept Reduces Transfusion Burden Compared With Epoetin Alfa - 7 months ago FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy - 9 months ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - about 1 year ago
10	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: WHO scientists question Grail’s plan for evaluating its multi-cancer Galleri blood test - 9 months ago

Journalists covering Multiple Myeloma,monoclonal gammopathy of undetermined significance,hematology,bone marrow